Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Diagnostic Biomarker Found for Human Renal Cell Carcinoma

By Drug Discovery Trends Editor | January 27, 2009

Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer. A team based at the University of Chicago shows that the biomarker known as SPOP is produced by 99 percent of clear cell renal cell carcinomas, but not by normal kidney tissue.

Physicians could use SPOP levels to confirm or rule out a diagnosis of renal cell carcinoma (RCC). It could also help them determine the original source of cancers that had spread to other organs from an unknown primary tumor.

‘This could serve as a diagnostic tool, lead us to new drug targets and potentially help us detect kidney cancers sooner,’ said study-director Kevin White, PhD, professor of human genetics, and ecology and evolution, and director of the Institute for Genetics and Systems Biology at the University of Chicago. ‘It also confirms our strategy of using genomics and systems-level analysis of model organisms such as fruit flies to identify factors that play crucial roles in human disease.’

The study began with the fly genome. White and colleagues, who study gene regulation, wanted to measure the downstream effects of two key genes, known as Eve and Ftz, which control early steps in the development of flies, beginning just after the eggs are laid.

Because Eve and Ftz regulate the activity of other genes, and many of those genes control the activity of additional genes, both had a large impact. Eve influences the expression of 1,074 different genes and Ftx impacts 1,310 genes.

When they narrowed their search to genes directly impacted, the total fell to 235 genes. About 20 percent of those target genes regulate transcription, the activation of other genes, and 40 percent controlled developmental processes.

About 150 of those target genes have human equivalents. When the researchers ranked those 150 genes according to their impact in flies, the top candidate was a gene known as CG9924, or Roadkill, the central player in a major hub of networked genes and a crucial component in the development of the nervous system. SPOP, the human equivalent, is about 80 percent identical to Roadkill.

Looking closer, they determined that SPOP appeared to play a role not just in development but also in human cancers. It interacts with cell signaling pathways—JNK and RAS—that frequently go awry in multiple human cancers.

At this point, the researchers shifted their focus from fly genetics to human cancer. When they screened hundreds of tissue samples from 18 different tumor types, acquired from patients having surgery, they found that 85 percent of renal cell carcinomas produced high amounts of SPOP, while normal kidney tissue was uniformly negative.

When they looked at 300 renal cell cancer samples, 77 percent were positive for SPOP. All normal kidney samples were negative.

About 75 percent of all renal cell cancers are clear cell RCC. The researchers found that 99 percent of the clear cell RCC samples showed evidence of elevated SPOP. The SPOP test even revealed that a few tumors had originally been misdiagnosed as clear cell RCC. Those turned out to be other types of kidney cancer when examined more closely by pathologists.

‘These results indicate that SPOP is a highly sensitive and specific diagnostic biomarker for clear cell RCC,’ the authors conclude, ‘and can help distinguish histological subtypes of RCC.’

It could also be used to help identify the primary tumor in metastatic cancers, important in treatment decisions.

Release Date: January 26, 2009
Source: University of Chicago Medical Center 


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE